trimetrexate has been researched along with Granulocytic Leukemia in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nusbaum, NJ | 1 |
| Abraham, T | 1 |
1 other study available for trimetrexate and Granulocytic Leukemia
| Article | Year |
|---|---|
AZT modulation of trimetrexate myelotoxicity: evidence from an HL60 model.
Topics: Acquired Immunodeficiency Syndrome; Humans; Leukemia, Myeloid; Models, Biological; Trimetrexate; Tum | 1995 |